The MCTRC, in partnership with the Quebec 鈥� Clinical Research Organization in Cancer (Q-CROC), implements investigator-initiated biopsy-driven translational research, via its clinical research infrastructure. The overall aim is to identify molecular signatures and mechanisms of resistance to particular treatment in the clinical setting. Researchers involved in the biomarker/biopsy-driven research group apply OMIC technologies to look at hundreds of thousands of genes, proteins and other compounds simultaneously to identify biomarkers and molecular signatures associated with disease type, stage and outcome of cancer treatment.
Theme leader:
Dr. Gerald Batist, Lady Davis Institute for Medical Research, 平特五不中
Members:
Dr. Moulay Alaoui-Jamali, Lady Davis Institute for Medical Research, 平特五不中
Dr. Sarit Assouline, Jewish General Hospital, 平特五不中
Dr. Mark Basik, Lady Davis Institute for Medical Research, 平特五不中
Dr. Christoph Borchers, Lady Davis Institute for Medical Research, 平特五不中
Dr. Cristiano Ferrario, Jewish General Hospital, 平特五不中
Dr. Walter Gotlieb, Lady Davis Institute for Medical Research, 平特五不中
Dr. Celia Greenwood, Lady Davis Institute for Medical Research, 平特五不中
Dr. Nathalie Johnson, Lady Davis Institute for Medical Research, 平特五不中
Dr. Claudia Kleinman, Lady Davis Institute for Medical Research, 平特五不中
Dr. Bernard Lesperance, Universit茅 de Montr茅al
Dr. Wilson Miller, Lady Davis Institute for Medical Research, 平特五不中
Dr. Alan Spatz, Lady Davis Institute for Medical Research, 平特五不中
